Zacks Rating on Impax Laboratories (IPXL)

Impax Laboratories (IPXL) : The consensus on Impax Laboratories (IPXL) based on 9 analyst recommendation on the company stock is 2.33, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 6 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Impax Laboratories (IPXL) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $32 and the lowest price target forecast is $24. The average forecast of all the analysts is $28 and the expected standard deviation is $3.16.


Shares of Impax Laboratories Inc. appreciated by 4.37% during the last five trading days but lost 22.12% on a 4-week basis. Impax Laboratories Inc. has dropped 26.82% during the last 3-month period . Year-to-Date the stock performance stands at -44.18%. Impax Laboratories (NASDAQ:IPXL): On Tuesdays trading session , Opening price of the stock was $24.03 with an intraday high of $24.27. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $23.85. However, the stock managed to close at $23.87, a loss of 0.58% for the day. On the previous day, the stock had closed at $24.01. The total traded volume of the day was 1,162,045 shares.

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Companys generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.